47,184 Becton, Dickinson and Company $BDX Shares Bought by ProShare Advisors LLC

Key Points

• ProShare Advisors increased its Becton, Dickinson and Company stake by 4.4% in the third quarter, purchasing 47,184 shares and bringing its holdings to 1.12 million shares valued at approximately $200.4 million. Institutional investors collectively own 86.97% of BDX.
• BDX reported quarterly revenue of $4.98 billion and adjusted earnings of $3.23 per share, beating analyst estimates, while revenue rose 5.4% year over year. The company issued fiscal 2026 EPS guidance of $12.62–$12.72.
• Analyst sentiment is moderately bullish, with a consensus “Moderate Buy” rating and a $185.07 price target, although recent insider activity was negative as executives sold a combined 6,907 shares worth about $1.27 million.

ProShare Advisors LLC boosted its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 4.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,119,563 shares of the medical instruments supplier's stock after purchasing an additional 47,184 shares during the quarter. ProShare Advisors LLC owned about 0.41% of Becton, Dickinson and Company worth $200,402,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Vise Technologies Inc. purchased a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at $814,000. Cidel Asset Management Inc. increased its position in Becton, Dickinson and Company by 3.0% during the 3rd quarter. Cidel Asset Management Inc. now owns 3,219 shares of the medical instruments supplier's stock valued at $576,000 after buying an additional 95 shares in the last quarter. Avestar Capital LLC purchased a new stake in shares of Becton, Dickinson and Company during the third quarter valued at $332,000. International Assets Investment Management LLC purchased a new stake in Becton, Dickinson and Company during the third quarter valued at $16,110,000. Finally, Brian Low Financial Group LLC lifted its position in Becton, Dickinson and Company by 5.5% during the third quarter. Brian Low Financial Group LLC now owns 9,357 shares of the medical instruments supplier's stock valued at $1,675,000 after purchasing an additional 486 shares in the last quarter. Institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Trading Down 0.4%

NYSE BDX opened at $197.48 on Friday. The firm has a 50-day moving average price of $186.58 and a 200 day moving average price of $170.26. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $200.47. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $54.41 billion, a P/E ratio of 59.48, a P/E/G ratio of 13.34 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The firm had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period last year, the business posted $3.68 EPS. Becton, Dickinson and Company's quarterly revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on BDX. Piper Sandler increased their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Friday, August 7th. Barclays began coverage on Becton, Dickinson and Company in a research report on Wednesday, October 7th. They set an "underweight" rating and a $165.00 price target on the stock. Citigroup reiterated a "buy" rating on shares of Becton, Dickinson and Company in a research report on Thursday, August 13th. TD Cowen raised their target price on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a "hold" rating in a research report on Wednesday, August 5th. Finally, Zacks Research raised shares of Becton, Dickinson and Company from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $185.07.

Insider Buying and Selling

In other Becton, Dickinson and Company news, CEO Thomas Polen, Jr. sold 4,152 shares of the firm's stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the transaction, the chief executive officer owned 110,163 shares of the company's stock, valued at $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares of the company's stock, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 6,907 shares of company stock worth $1,269,128. Insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD's products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.